Inhibition of CARM1 can further decrease the HAT activity of CBP and the expression of target genes, leading to synthetic lethality in diffuse large B cell lymphoma (DLBCL) tumors with mutant CREBBP/EP300 [57]. This evidence concerns the gene CARM1 and diffuse large B-cell lymphoma.